07.10.19
Astellas has appointed Chelsea Glinski as national vice president, Oncology Sales, Astellas US. In this role, Glinski will oversee U.S. sales for the XTANDI brand, and contribute to the growth and development of the oncology sales organization overall.
Glinski previously served as executive director of Astellas' market access and reimbursement strategy, where she led the design and operations of reimbursement services and patient support programs across the Astellas portfolio. In addition, Glinski held operational roles in Astellas' Health Systems Business Unit. Recently, she was recognized by the Healthcare Businesswomen's Association (HBA) as a 2019 Luminary.
"At Astellas, we strive to make every day better for those impacted by cancer," said Mark Reisenauer, senior vice president, Oncology Business Unit. "Chelsea's breadth of healthcare experience, with a career that started in research and expanded into strategy and operations, and most recently in overseeing patient support and access programs, makes her a natural fit to help Astellas' oncology franchise continue to grow and evolve."
Glinski previously served as executive director of Astellas' market access and reimbursement strategy, where she led the design and operations of reimbursement services and patient support programs across the Astellas portfolio. In addition, Glinski held operational roles in Astellas' Health Systems Business Unit. Recently, she was recognized by the Healthcare Businesswomen's Association (HBA) as a 2019 Luminary.
"At Astellas, we strive to make every day better for those impacted by cancer," said Mark Reisenauer, senior vice president, Oncology Business Unit. "Chelsea's breadth of healthcare experience, with a career that started in research and expanded into strategy and operations, and most recently in overseeing patient support and access programs, makes her a natural fit to help Astellas' oncology franchise continue to grow and evolve."
